

August 1, 2025  
Corporate Name: AGC Inc.  
(Code Number: 5201; TSE Prime Market)  
(URL: <https://www.agc.com>)  
President & CEO: Yoshinori Hirai  
Contact: Kazumi Tamaki, Executive Officer, General Manager,  
Corporate Communications & Investor Relations Division  
(Tel: +81-3-3218-5603)

## Consolidated Financial Results for the Six Months ended June 30, 2025 (IFRS basis)

(Figures are rounded down to the nearest million)

### 1. Financial Results for the Six months ended June 30, 2025 (January 1 through June 30, 2025)

#### (1) Consolidated operating results

(% represents the change from the same period in the previous fiscal year)

	For the Six months ended June 30, 2025		For the Six months ended June 30, 2024	
	Millions of yen	%	Millions of yen	%
Net sales	995,474	(1.9)	1,015,195	3.0
Operating profit	54,022	(4.7)	56,690	(11.9)
Profit (loss) before tax	33,751	-	(92,388)	-
Profit (loss) for the period	18,357	-	(106,744)	-
Profit (loss) for the period attributable to owners of the parent	13,905	-	(114,500)	-
Total comprehensive income for the period	(42,850)	-	79,314	(50.9)
Basic earnings per share (yen)	65.59		(540.26)	
Diluted earnings per share (yen)	65.48		(540.26)	

#### (2) Consolidated financial position

	FY2025 second quarter (as of June 30, 2025)	FY2024 (as of December 31, 2024)
Total assets (millions of yen)	2,804,883	2,889,665
Total equity (millions of yen)	1,600,361	1,671,697
Equity attributable to owners of the parent (millions of yen)	1,380,971	1,435,787
Equity attributable to owners of the parent ratio (%)	49.2	49.7

### 2. Dividends

(Unit: yen)

	FY2024	FY2025	FY2025 (forecast)
End of first quarter	-	-	-----
End of second quarter	105.00	105.00	-----
End of third quarter	-	-----	-
End of fiscal year	105.00	-----	105.00
Total	210.00	-----	210.00

Note: Revision of the dividends forecast from the latest official forecast: No

### 3. Forecast for FY2025 (January 1 through December 31, 2025)

(% represents the change from the same period in the previous fiscal year)

	Full year	
	Millions of yen	%
Net sales	2,050,000	(0.9)
Operating profit	120,000	(4.6)
Profit before tax	97,000	-
Profit for the period	68,000	-
Profit for the period attributable to owners of the parent	57,000	-
Basic earnings per share (yen)	268.84	

Note: Revision of the forecast for FY2025 consolidated operating results from the latest official forecast: Yes

#### \*Notes

(1) Significant changes in the scope of consolidation during the six months ended June 30, 2025: No

(2) Changes in Accounting Policies and Changes in Accounting Estimates

- i. Changes in accounting policies required by IFRS: No
- ii. Changes in accounting policies other than "i" above: No
- iii. Changes in accounting estimates: Yes

Note: For details, please refer to “2. Condensed Interim Consolidated Financial Statements (IFRS) and major notes (5) Notes to the Condensed Interim Consolidated Financial Statements, (Changes in Accounting Estimates)” on page 13.

(3) Number of shares issued (common share)

- i. Number of shares issued (including treasury share) at the end of the period
  - As of June 30, 2025: 217,434,681
  - As of December 31, 2024: 217,434,681
- ii. Number of treasury share at the end of the period
  - As of June 30, 2025: 5,079,912
  - As of December 31, 2024: 5,156,771
- iii. Average number of shares issued during the period
  - For the six months ended June 30, 2025: 211,999,347
  - For the six months ended June 30, 2024: 211,933,883

\*This interim consolidated financial statement is outside the scope of quarterly review procedures.

#### \*Appropriate Use of Forecast and Other Information and Other Matters

The above forecast is the assumptions of the Group's management on the basis of currently available information and, as such, contain risks and uncertainties. For this reason, investors are advised not to base investment decisions solely on these prospective results. Please note that actual results may materially differ from the projection due to such various factors as business and market environment the Group is active in, currency exchange rate fluctuations, and others.

#### \*Supplementary Material for the Quarterly Financial Results

Supplementary material (Financial Results for the six months ended June 30, FY2025) will be published today on TD-net for viewing in Japan, and on our Website.

**(Attached Documents)**

**INDEX**

1. Overview of Operating Results	2
(1) Analysis of Operating Results	2
(2) Analysis of Financial Position	3
2. Condensed Interim Consolidated Financial Statements (IFRS) and major notes	4
(1) Condensed Interim Consolidated Statements of Financial Position	4
(2) Condensed Interim Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income	6
(Condensed Interim Consolidated Statements of Profit or Loss)	6
(Condensed Interim Consolidated Statements of Comprehensive Income)	7
(3) Condensed Interim Consolidated Statements of Changes in Equity	8
(4) Condensed Interim Consolidated Statements of Cash Flows	12
(5) Notes to the Condensed Interim Consolidated Financial Statements	13
(Notes regarding assumption of a going concern)	13
(Changes in Accounting Policies)	13
(Material Accounting Policies)	13
(Changes in Accounting Estimates)	13
(Segment Information)	14
(Other Income and Other Expenses)	16
(Significant Subsequent Events)	16

## 1. Overview of Operating Results

### (1) Analysis of Operating Results

During the six months ended June 30, 2025, compared to the same period of the previous fiscal year, the automotive glass business saw improvements in product mixes and the effects of pricing policy. The sales prices of Performance Chemicals also increased. On the other hand, the sales of architectural glass were affected by a decrease in shipments in Europe and the transfer of the Russian business in February 2024. The sales prices of Essential Chemicals declined.

As a result, net sales amounted to ¥995.5 billion, down ¥19.7 billion, or a 1.9% decrease year on year, due in part to the decline in sales caused by the appreciation of the yen. Operating profit decreased by ¥2.7 billion (4.7%) to ¥54.0 billion due to cost deterioration such as that seen in the form of higher raw materials and fuel prices, despite the effects of measures to improve profitability. Profit before tax for the period increased by ¥126.1 billion to ¥33.8 billion (loss before tax for the same period of the previous fiscal year was ¥92.4 billion) due to the absence of losses on the sale of shares of subsidiaries and associates in line with the transfer of the Russian business and the impairment losses that occurred in the biopharmaceuticals CDMO business, which had been included in other expenses in the same period of the previous fiscal year. Profit attributable to owners of the parent increased by ¥128.4 billion to ¥13.9 billion (loss attributable to owners of the parent for the same period of the previous fiscal year was ¥114.5 billion).

#### Overview of reportable segments

(Unit: billions of yen)

	Net sales		Operating profit	
	For the Six months ended June 30, 2025	For the Six months ended June 30, 2024	For the Six months ended June 30, 2025	For the Six months ended June 30, 2024
Architectural Glass	210.8	224.7	3.2	10.2
Automotive	255.7	251.9	15.1	10.6
Electronics	168.1	169.3	24.4	20.0
Chemicals	285.9	290.4	22.5	27.7
Life Science	63.5	63.6	(11.9)	(14.1)
Ceramics & Others	28.0	42.4	0.6	2.4
Eliminations or company-wide	(16.6)	(27.1)	0.0	0.0
Total	995.5	1,015.2	54.0	56.7

The performance of each reportable segment for the six months ended June 30, 2025 are as follows.

#### - Architectural Glass

In Europe & Americas, net sales decreased compared to the previous year due to lower shipments in Europe, as well as negative impact from the transfer of the Russian business and the appreciation of the yen, despite the positive effect of pricing policies. In Asia, net sales decreased compared to the previous year due to lower sales prices in Indonesia and other regions, as well as lower shipments.

As a result, net sales of Architectural Glass segment for the period were ¥210.8 billion, down ¥13.9 billion, or a 6.2% decrease, from the same period of the previous fiscal year. Operating profit decreased by ¥6.9 billion (68.2%) to ¥3.2 billion due to the aforementioned factors of lower revenue and higher raw materials and fuel prices.

#### - Automotive

Automotive net sales increased year on year due to an increase in shipments in Japan combined with a decline in Europe & America, as well as improvements in product mix and the effects of pricing policies.

As a result, net sales of Automotive segment for the period were ¥255.7 billion, up ¥3.8 billion, or a 1.5% increase, from the same period of the previous fiscal year. Operating profit increased by ¥4.6 billion, or 43.3%, to ¥15.1 billion.

- Electronics

Display net sales were at the same level seen in the previous year due to a decrease in shipments of specialty glass for displays which occurred despite an increase in shipments of LCD glass substrates. Electronic Materials net sales decreased year on year due to decreases in shipments of photomask blanks for EUV lithography and other semiconductor-related materials, as well as the impact of the appreciation of the yen.

As a result, net sales of Electronics segment for the period were ¥168.1 billion, down ¥1.2 billion, or a 0.7% decrease, from the same period of the previous fiscal year. Operating profit increased by ¥4.4 billion, or 22.0%, to ¥24.4 billion, due to the effects of measures aimed at improving profitability.

- Chemicals

Essential Chemicals net sales decreased year on year as the sales prices of PVC declined. Performance Chemicals net sales rose year on year thanks to the impact of higher sales prices.

As a result, net sales of Chemicals segment for the period were ¥285.9 billion, down ¥4.6 billion, or a 1.6% decrease, from the same period of the previous fiscal year. Operating profit decreased by ¥5.1 billion (18.5%) to ¥22.5 billion, mainly due to a deterioration in manufacturing costs associated with regular facility repairs, in addition to the aforementioned factors involved in lower net sales.

- Life Science

Life Science net sales were at the same level as they were in the same period of the previous fiscal year due to factors involved in lower net sales, such as the absence of one-off revenues from the settlement of contracted projects recorded in the same period of the previous fiscal year and production issues at Boulder site (U.S), in addition to the effects of increased revenues from the start of the operation of expanded facilities in the biopharmaceuticals CDMO.

As a result, net sales of Life Science segment for the period were ¥63.5 billion, down ¥0.1 billion, or a 0.1% decrease, from the same period of the previous fiscal year. Operating profit, despite the effects of fixed-cost reduction measures deployed for the biopharmaceuticals CDMO, increased by ¥2.2 billion to a loss of ¥11.9 billion, due to the aforementioned factors contributing to lower revenue.

## (2) Analysis of Financial Position

- Assets

Total assets as of the end of the second quarter under review were ¥2,804.9 billion, down ¥84.8 billion from the end of the previous fiscal year. This was mainly due to decreases in property, plant and equipment and trade receivables.

- Liabilities

Total liabilities as of the end of the second quarter under review were ¥1,204.5 billion, down ¥13.4 billion from the end of the previous fiscal year. This was mainly due to decreases in trade payables and income tax payables.

- Equity

Total equity as of the end of the second quarter under review was ¥1,600.4 billion, down ¥71.3 billion from the end of the previous fiscal year. This decrease was mainly due to a decrease in exchange differences on translation of foreign operations affected by the appreciation of the yen compared to the end of the previous fiscal year.

## 2. Condensed Interim Consolidated Financial Statements (IFRS) and major notes

### (1) Condensed Interim Consolidated Statements of Financial Position

(Unit: millions of yen)

	As of December 31, 2024	As of June 30, 2025
Assets		
Current assets		
Cash and cash equivalents	107,988	100,492
Trade receivables	332,442	310,030
Inventories	454,143	457,674
Other receivables	58,221	52,754
Income tax receivables	16,556	6,231
Other current assets	25,103	28,939
(Subtotal)	994,455	956,123
Assets held for sale	6,815	6,603
Total current assets	1,001,270	962,726
Non-current assets		
Property, plant and equipment	1,550,862	1,518,781
Goodwill	49,774	48,879
Intangible assets	52,291	52,102
Investments accounted for using equity method	30,521	32,092
Other financial assets	68,798	60,765
Deferred tax assets	39,019	42,015
Other non-current assets	97,127	87,519
Total non-current assets	1,888,395	1,842,156
Total assets	2,889,665	2,804,883

(Unit: millions of yen)

	As of December 31, 2024	As of June 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade payables	201,803	195,008
Short-term interest-bearing debt	129,940	161,568
Long-term interest-bearing debt due within one year	109,921	95,510
Other payables	214,523	221,637
Income tax payables	21,376	15,432
Provisions	1,361	1,620
Other current liabilities	21,183	22,380
(Subtotal)	700,110	713,159
Liabilities associated with assets held for sale	8,661	8,152
Total current liabilities	708,771	721,312
Non-current liabilities		
Long-term interest-bearing debt	409,876	393,714
Deferred tax liabilities	22,865	18,444
Post-employment benefit liabilities	51,370	50,415
Provisions	12,883	11,733
Other non-current liabilities	12,199	8,902
Total non-current liabilities	509,196	483,209
Total liabilities	1,217,967	1,204,521
Equity		
Share capital	90,873	90,873
Capital surplus	95,781	95,813
Retained earnings	744,766	737,710
Treasury shares	(26,767)	(26,369)
Other components of equity	531,134	482,943
Total equity attributable to owners of the parent	1,435,787	1,380,971
Non-controlling interests	235,909	219,389
Total equity	1,671,697	1,600,361
Total liabilities and equity	2,889,665	2,804,883

(2) Condensed Interim Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income

(Condensed Interim Consolidated Statements of Profit or Loss)

(Unit: millions of yen)

	For the six months ended June 30, 2024 (Jan. 1 through Jun. 30, 2024)	For the six months ended June 30, 2025 (Jan. 1 through Jun. 30, 2025)
Net sales	1,015,195	995,474
Cost of sales	(774,966)	(759,571)
Gross profit	240,229	235,903
Selling, general and administrative expenses	(184,444)	(183,379)
Share of profit (loss) of associates and joint ventures accounted for using equity method	905	1,499
Operating profit	56,690	54,022
Other income	15,222	3,447
Other expenses	(162,428)	(20,756)
Business profit (loss)	(90,515)	36,712
Finance income	6,926	4,880
Finance costs	(8,799)	(7,841)
Net finance income (costs)	(1,873)	(2,960)
Profit (loss) before tax	(92,388)	33,751
Income tax expenses	(14,356)	(15,394)
Profit (loss) for the period	(106,744)	18,357
Attributable to:		
Owners of the parent	(114,500)	13,905
Non-controlling interests	7,755	4,452
Earnings per share		
Basic earnings (loss) per share (yen)	(540.26)	65.59
Diluted earnings (loss) per share (yen)	(540.26)	65.48



## (Condensed Interim Consolidated Statements of Comprehensive Income)

(Unit: millions of yen)

	For the six months ended June 30, 2024 (Jan. 1 through Jun. 30, 2024)	For the six months ended June 30, 2025 (Jan. 1 through Jun. 30, 2025)
Profit (loss) for the period	(106,744)	18,357
Other comprehensive income		
Components of other comprehensive income that will not be reclassified to profit or loss, net of tax		
Remeasurements of defined benefit plans	18,658	(4,308)
Net change in revaluation of financial assets measured at FVTOCI <sup>(Note)</sup>	6,043	(425)
Share of other comprehensive income of associates and joint ventures accounted for using equity method	(0)	(18)
Total	24,702	(4,752)
Components of other comprehensive income that will be reclassified to profit or loss, net of tax		
Cash flow hedges	1,519	(1,584)
Exchange differences on translation of foreign operations	159,836	(54,870)
Total	161,356	(56,455)
Other comprehensive income, net of tax	186,059	(61,207)
Total comprehensive income for the period	79,314	(42,850)
Attributable to:		
Owners of the parent	53,102	(32,761)
Non-controlling interests	26,212	(10,088)

(Note) FVTOCI: Fair Value Through Other Comprehensive Income

(3) Condensed Interim Consolidated Statements of Changes in Equity  
For the six months ended June 30, 2024

(Unit: millions of yen)

	Equity attributable to owners of the parent					
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	
					Remeasurements of defined benefit plans	Net change in revaluation of financial assets measured at FVTOCI <sup>(Note)</sup>
Balance as of January 1, 2024	90,873	97,056	872,547	(27,338)	29,737	25,317
Changes in equity						
Comprehensive income						
Profit(loss) for the period	-	-	(114,500)	-	-	-
Other comprehensive income	-	-	-	-	18,479	6,037
Total comprehensive income for the period	-	-	(114,500)	-	18,479	6,037
Transactions with owners						
Dividends	-	-	(22,278)	-	-	-
Acquisition of treasury shares	-	-	-	(1,252)	-	-
Disposal of treasury shares	-	-	(191)	1,786	-	-
Changes in ownership interests in subsidiaries that do not result in loss of control	-	5	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	7,306	-	-	(7,306)
Share-based payment transactions	-	(1,281)	-	-	-	-
Others (business combinations and others)	-	(5)	-	-	-	-
Total transactions with owners	-	(1,281)	(15,163)	533	-	(7,306)
Balance as of June 30, 2024	90,873	95,774	742,883	(26,804)	48,217	24,049

(Note) FVTOCI: Fair Value Through Other Comprehensive Income

For the six months ended June 30, 2024

(Unit: millions of yen)

	Equity attributable to owners of the parent			Total	Non-controlling interests	Total equity
	Other components of equity		Total			
	Cash flow hedges	Exchange differences on translation of foreign operations				
Balance as of January 1, 2024	(6,167)	365,053	413,941	1,447,080	207,258	1,654,338
Changes in equity						
Comprehensive income						
Profit(loss) for the period	-	-	-	(114,500)	7,755	(106,744)
Other comprehensive income	1,693	141,391	167,602	167,602	18,456	186,059
Total comprehensive income for the period	1,693	141,391	167,602	53,102	26,212	79,314
Transactions with owners						
Dividends	-	-	-	(22,278)	(7,551)	(29,830)
Acquisition of treasury shares	-	-	-	(1,252)	-	(1,252)
Disposal of treasury shares	-	-	-	1,595	-	1,595
Changes in ownership interests in subsidiaries that do not result in loss of control	-	-	-	5	(25)	(19)
Transfer from other components of equity to retained earnings	-	-	(7,306)	-	-	-
Share-based payment transactions	-	-	-	(1,281)	-	(1,281)
Others (business combinations and others)	-	-	-	(5)	-	(5)
Total transactions with owners	-	-	(7,306)	(23,217)	(7,576)	(30,794)
Balance as of June 30, 2024	(4,473)	506,445	574,237	1,476,965	225,893	1,702,858

For the six months ended June 30, 2025

(Unit: millions of yen)

	Equity attributable to owners of the parent					
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity	
					Remeasurements of defined benefit plans	Net change in revaluation of financial assets measured at FVTOCI <sup>(Note)</sup>
Balance as of January 1, 2025	90,873	95,781	744,766	(26,767)	23,921	18,687
Changes in equity						
Comprehensive income						
Profit for the period	-	-	13,905	-	-	-
Other comprehensive income	-	-	-	-	(4,725)	(446)
Total comprehensive income for the period	-	-	13,905	-	(4,725)	(446)
Transactions with owners						
Dividends	-	-	(22,289)	-	-	-
Acquisition of treasury shares	-	-	-	(6)	-	-
Disposal of treasury shares	-	-	(196)	405	-	-
Changes in ownership interests in subsidiaries that do not result in loss of control	-	-	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	1,525	-	-	(1,525)
Share-based payment transactions	-	32	-	-	-	-
Others (business combinations and others)	-	-	-	-	-	-
Total transactions with owners	-	32	(20,960)	398	-	(1,525)
Balance as of June 30, 2025	90,873	95,813	737,710	(26,369)	19,195	16,715

(Note) FVTOCI: Fair Value Through Other Comprehensive Income

For the six months ended June 30, 2025

(Unit: millions of yen)

	Equity attributable to owners of the parent			Total	Non-controlling interests	Total equity
	Other components of equity		Total			
	Cash flow hedges	Exchange differences on translation of foreign operations				
Balance as of January 1, 2025	(497)	489,023	531,134	1,435,787	235,909	1,671,697
Changes in equity						
Comprehensive income						
Profit for the period	-	-	-	13,905	4,452	18,357
Other comprehensive income	(1,591)	(39,902)	(46,666)	(46,666)	(14,541)	(61,207)
Total comprehensive income for the period	(1,591)	(39,902)	(46,666)	(32,761)	(10,088)	(42,850)
Transactions with owners						
Dividends	-	-	-	(22,289)	(6,431)	(28,720)
Acquisition of treasury shares	-	-	-	(6)	-	(6)
Disposal of treasury shares	-	-	-	208	-	208
Changes in ownership interests in subsidiaries that do not result in loss of control	-	-	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	(1,525)	-	-	-
Share-based payment transactions	-	-	-	32	-	32
Others (business combinations and others)	-	-	-	-	-	-
Total transactions with owners	-	-	(1,525)	(22,054)	(6,431)	(28,485)
Balance as of June 30, 2025	(2,089)	449,121	482,943	1,380,971	219,389	1,600,361

(4) Condensed Interim Consolidated Statements of Cash Flows

(Unit: millions of yen)

	For the six months ended June 30, 2024 (Jan. 1 through Jun. 30, 2024)	For the six months ended June 30, 2025 (Jan. 1 through Jun. 30, 2025)
Cash flows from operating activities		
Profit (loss) before tax	(92,388)	33,751
Depreciation and amortization	91,528	88,204
Impairment losses	119,182	8,020
Interest and dividend income	(6,115)	(4,830)
Interest expenses	8,417	7,210
Share of loss (profit) of associates and joint ventures accounted for using equity method	(905)	(1,499)
Loss (gain) on sale or disposal of fixed assets	1,871	1,089
Decrease (increase) in trade receivables	13,162	15,534
Decrease (increase) in inventories	(5,670)	(9,496)
Increase (decrease) in trade payables	(21,945)	(3,450)
Others	52,062	3,172
Subtotal	159,199	137,707
Interest and dividends received	7,219	5,114
Interest paid	(8,767)	(7,115)
Income taxes refund (paid)	(15,423)	(18,566)
Cash flows from operating activities	142,227	117,139
Cash flows from investing activities		
Purchase of property, plant and equipment, and intangible assets	(115,527)	(91,739)
Proceeds from sale of property, plant and equipment	681	2,969
Purchase of other financial assets	(384)	(292)
Proceeds from sale and redemption of other financial assets	15,716	3,538
Proceeds from sale of subsidiaries and associates or other businesses	22,121	—
Others	(851)	(2,202)
Cash flows from investing activities	(78,243)	(87,726)
Cash flows from financing activities		
Changes in short-term interest-bearing debt	(18,088)	30,384
Proceeds from borrowing or issuing long-term interest-bearing debt	15,467	34,694
Repayment or redemption of long-term interest-bearing debt	(74,361)	(70,783)
Payments for acquisition of interests in subsidiaries from non-controlling interests	(12)	—
Proceeds from non-controlling interests	263	244
Acquisition of treasury shares	(1,252)	(6)
Dividends paid	(22,278)	(22,289)
Dividends paid to non-controlling interests	(7,815)	(6,092)
Others	855	76
Cash flows from financing activities	(107,222)	(33,770)
Effect of exchange rate changes on cash and cash equivalents	6,832	(3,039)
Net changes in cash and cash equivalents resulting from transfer to assets held for sale	(781)	(98)
Net increase (decrease) in cash and cash equivalents	(37,187)	(7,495)
Cash and cash equivalents at the beginning of the period	146,061	107,988
Cash and cash equivalents at the end of the period	108,874	100,492

(5) Notes to the Condensed Interim Consolidated Financial Statements

(Notes regarding assumption of a going concern)

Not applicable

(Changes in Accounting Policies)

The material accounting policies adopted for the Group's Condensed Interim Consolidated Financial Statements are the same as those for the Consolidated Financial Statements for the fiscal year ended December 31, 2024.

(Material Accounting Policies)

"Operating profit" in the Group's Condensed Interim Consolidated Statements of Profit or Loss is an indicator that facilitates continuous comparisons and evaluations of the Group's business performance. Main items of "other income" and "other expenses" are foreign exchange gains and losses, gain on sale of fixed assets, losses on disposal of fixed assets, impairment losses and expenses for restructuring programs. "Business profit" includes all income and expenses before finance income, finance costs and income tax expenses.

The Group calculated income tax expenses for the six months ended June 30, 2025, based on the estimated average annual effective tax rate.

(Changes in Accounting Estimates)

In preparing the Group's Condensed Interim Consolidated Financial Statements, judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses are made. Therefore actual results could differ from these estimates.

Estimates and assumptions that have a significant effect on the amounts recognized in the Group's condensed interim consolidated financial statements are in principle the same as the previous fiscal year, with the exception of the item below.

Estimates and their assumptions are reviewed continuously. The effect of reviewing estimates and assumptions is recognized in the period in which those estimates and assumptions are reviewed and in future periods.

(Impairment losses)

During the period, AGC Biologics, Inc., a contract developer and manufacturer of biopharmaceutical APIs included within the Life Science segment, saw a significant decrease in terms of its forecast for future orders and operations and have decided to proceed with structural reforms regarding the Boulder site and the Longmont site in Colorado, USA. Accordingly, the cash-generating units to which property, plant and equipment and intangible assets belonged were classified, resulting in the cash-generating unit showing signs of impairment. As a result of an impairment test, we recognized an impairment loss of ¥7,724 million, since the recoverable amount based on the fair value minus the disposal costs, was lower than the book value of the cash-generating unit. In the valuation of fair value less costs of disposal, the market approach and cost approach were mainly used. Due to the inclusion of non-observable inputs such as third-party valuation amounts, the fair value hierarchy is classified as Level 3.

(Segment Information)

The Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are reviewed regularly by the Group's chief operating decision maker to make decisions about resources to be allocated to the segment and assess performance. The Group has six in-house companies by product and service: Architectural Glass Europe & Americas, Architectural Glass Asia Pacific, Automotive, Electronics, Chemicals, and Life Science. Each in-house company operates worldwide, formulating comprehensive domestic and overseas strategies for its products and services.

In addition, the Architectural Glass Europe & Americas and Architectural Glass Asia Pacific companies are considered to share economic characteristics, because they are united in their efforts to share information on technological development and production related to float and architectural processing, to create social value of GHG reduction and product contribution to climate change issues, and to take a common commitment for long-term profitability indicators and others, and they have similarities in products and sales markets.

Thus, the Group has five reportable segments: Architectural Glass, Automotive, Electronics, Chemicals and Life Science.

The main products and services of each reportable segment are as follows.

Reportable segment	Main products and services
Architectural Glass	Architectural figured glass, Architectural processing glass (Insulating glass, Toughened glass, Laminated glass)
Automotive	Automotive glass, Cover glass for car-mounted displays
Electronics	Display Glass substrates for TFT-LCD/OLED, Specialty Glass for displays Electronic Materials Materials for semiconductor, Optical materials
Chemicals	Essential Chemicals Caustic soda, Polyvinyl chloride resin, Urethane Performance Chemicals Fluorinated related products (Resins, Gases, Solvents), Iodine-related products
Life Science	CDMO services for small molecule pharmaceuticals, agrochemicals, biopharmaceuticals Intermediates and Active Ingredients of synthetic pharmaceutical and agrochemical



For the six months ended June 30, 2024 (January 1 through June 30, 2024)

(Unit: millions of yen)

	Reportable segments					Ceramics/ Others	Total	Adjustments	Amount reported on condensed interim consolidated statements of profit or loss
	Architectural Glass	Automotive	Electronics	Chemicals	Life Science				
Sales to external customers	223,470	251,785	168,620	288,558	61,647	21,112	1,015,195	-	1,015,195
Inter-segment sales	1,222	79	675	1,863	1,956	21,257	27,054	(27,054)	-
Total sales	224,692	251,864	169,295	290,422	63,604	42,370	1,042,249	(27,054)	1,015,195
Segment profit (loss) (Operating profit)	10,163	10,551	20,019	27,663	(14,115)	2,374	56,656	33	56,690
Profit (loss) for the period	-	-	-	-	-	-	-	-	(106,744)

The amounts of inter-segment sales are primarily based on market prices and manufacturing cost.

Ceramics/Others mainly handles ceramics products, logistics and financial services.

For the six months ended June 30, 2025 (January 1 through June 30, 2025)

(Unit: millions of yen)

	Reportable segments					Ceramics/ Others	Total	Adjustments	Amount reported on condensed interim consolidated statements of profit or loss
	Architectural Glass	Automotive	Electronics	Chemicals	Life Science				
Sales to external customers	209,447	255,572	167,249	283,698	61,694	17,811	995,474	-	995,474
Inter-segment sales	1,394	112	888	2,167	1,816	10,213	16,593	(16,593)	-
Total sales	210,842	255,684	168,138	285,866	63,510	28,025	1,012,068	(16,593)	995,474
Segment profit (loss) (Operating profit)	3,236	15,119	24,424	22,543	(11,927)	590	53,986	35	54,022
Profit for the period	-	-	-	-	-	-	-	-	18,357

The amounts of inter-segment sales are primarily based on market prices and manufacturing cost.

Ceramics/Others mainly handles ceramics products, logistics and financial services.

(Other Income and Other Expenses)

Other Income

(Unit: millions of yen)

	For the six months ended June 30 2024 (Jan. 1 through Jun. 30, 2024)	For the six months ended June 30 2025 (Jan. 1 through Jun. 30, 2025)
Foreign exchange gain	12,867	—
Gains on sale of fixed assets	—	1,764
Others	2,355	1,682
Total	15,222	3,447

Other Expenses

(Unit: millions of yen)

	For the six months ended June 30 2024 (Jan. 1 through Jun. 30, 2024)	For the six months ended June 30 2025 (Jan. 1 through Jun. 30, 2025)
Foreign exchange loss	—	(6,069)
Losses on disposal of fixed assets	(1,731)	(2,854)
Impairment losses	(119,182)	(8,020)
Expenses for restructuring programs	(1,269)	(2,579)
Losses on sale of shares of subsidiaries and associates	(36,482)	—
Others	(3,762)	(1,233)
Total	(162,428)	(20,756)

The main contents of impairment losses during the six months ended June 30, 2025 are described in (Changes in Accounting Estimates).

Impairment losses during the six months ended June 30, 2024 include amounts related to the contract development and manufacturing of biopharmaceutical active ingredients and gene and cell therapeutics in the Life Science segment amounting to 70,410 million yen for AGC Biologics, Inc., 28,904 million yen for AGC Biologics, A/S and 18,980 million yen for AGC Biologics, S.p.A.

Losses on sale of shares of subsidiaries and associates during the six months ended June 30, 2024 include a loss of 35,999 million yen from the transfer of Russian operations. The loss is mainly due to the reclassification adjustments on exchange differences on translation of foreign operations.

(Significant Subsequent Events)

No items to report